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ABSTRACT
After epidural administration of 15 mg 3,6-dinicotinoylmorphine (nicomorphine) in 10 
patients undergoing pulmonary surgery, the parent compound was quickly metabolized 
into the metabolites 6-mononicotinoyImorphine and morphine. The mean apparent 
half-lives (±SD) of elimination were 10 min (0*165 h db 0*053 h) for 3, ô'-dinicotînoyl- 
morphine and 111 h± 1 *23 h for 6-mononicotinoyimorphine. Morphine is subsequently 
metabolized into morphine-3-glucuronide and morphine-6-glucuronide* The apparent 
half-lives of morphine, morphine-3-glucuronide, and morphine-ô-glucuronide are 
similar: 3*63 h *  1*63 h, 4*10h^0’57h, and 4*20hdbl-64h respectively. The possible 
glucuronide conjugate of 6-mononicotinoylmorphine was not detected. The prodrug 
3,6-dinicotinoylmorphine was biotransformed into three active compounds: 6- 
mononicotinoylmorphine, morphine, and morphine-6~giucuronide.
k.uy words: pharmacokinetics; 3 ,6-dinicotinoylmorphine; 6-mononicotinoylmorphine; morphine;
glucuronides; anaesthetics; central; opioid
INTRODUCTION
Nicomorphine (3,6~dinicotinoylmorphine) has been introduced as an opioid 
analgesic for both systemic and perispinal use. Although the effectiveness of 
nicomorphine has been established, its action is considered not to relate to the 
compound itself. The lipid solubility of nicomorphine is almost sixfold higher
* Addressee for correspondence.
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in comparison to morphine1 as shown in Table 1. Nicomorphine is considered 
to be a ‘prodrag’, which exerts its analgesic effects through one or several 
of its metabolites.1,2 Chemical and enzymatic hydrolysis into 3- or 6- 
mononicotinoylmorphine and then into morphine occurs. Morphine is 
subsequently glucuronidated at the C3 and C6 positions, yielding morphine-
3-glucuronide and morphine-6-glucuronide. Opiate receptor binding studies 
indicate that the central analgesic activity of nicomorphine results from the 
actions of 6-mononicotinoylmorphine and morphine,3 It has now become 
apparent that morphine-6-glucuronide also has central analgesic activity like 
that of morphine.4
From studies in rats with l4C-labelled nicomorphine, it is known that the 
compound rapidly disappears from the blood and enters the brain. The 
appearance of its metabolites 6-mononicotinoylmorphine and morphine occurs 
concomitantly in both the blood and the brain,5
In order to measure 3,6-dinicotinoylmorphine and its metabolites in serum, 
we have developed a sensitive method of analysis by means of HPLC with UV 
and electrochemical detection6 and described the pharmacokinetic behaviour 
of nicomorphine and its unconjugated metabolites 6-mononicotinoylmorphine 
and morphine. Considering the fate of 3,6-dinicotinoylmorphine in the 
biological system and the apparent lack of intrinsic activity, the conclusion is 
justified that not the parent drug but rather the metabolites cause the drug to 
take effect in man. The serum concentration-time course of nicomorphine and 
its metabolites depends on the route of administration as shown earlier for the 
unconjugated compounds.7 9
In this study we investigated the pharmacokinetics of 3,6-dinicotinoyl­
morphine and its active metabolites with their glucuronide conjugates in 
patients after epidural administration of 15 mg.
Table L Physicochemical properties and receptor activities of nicomorphine and its 
metabolites:1 octanol/water distribution ratio; Pt lipid solubility at pH 7-1 and 7*4; 
ICjo, inhibition of 3H-fentanyl binding to whole brain membrane fraction, relative to
morphine (data from Lobbezoo et «/.)•*; ?, no data available
Drug
k < » .« • HO . |
Molecular weight
. , , . •*-• 4 * ► -S »« « *. «  ^« ‘  ^k » s n é± -*.»■». • «
P*7’b n u■iVo/W p*i IC50
DNN 495 7*45 34*67 10*70 16*34 0*01
6MNM 391 7*64 24*55 5-5 8-97 0*7
3MNM 391 7*61 94 9IP 91- 005
M 285 7-93 6*23 0*80 1-42 1
M3G 462 2*83c 9ft 9♦ 9t 9♦
M 6G 462 3*23° 9• 9 9 9
"Data from Nourypharma (Oss, The Netherlands). 
hpA^avalues in water.
2«cData from Corrupt et al.
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PATIENTS AND METHODS
Patients
The present study was carried out in n = 10 ASAI-III (according to the 
classification of the Association of American Anesthesiologists) patients, aged 
16-70 years (mean, 48 years ±19 years), with normal body weights. All patients 
were scheduled for thoracotomy or chest wall correction. Approval was given 
by the local ethics committee, and informed consent obtained from each 
patient. Excluded were patients with liver or kidney disfunction, known allergic 
reactions, use of opiates or opiate antagonists, or an expected blood loss 
greater than 500 mL during the surgical procedure.
Anaesthesia
All patients were premedicated orally with diazepam, 10 mg, 1 h before the 
induction of anaesthesia. A cannula IV (18G) drip was inserted into a suitable 
arm vein. Non-invasive monitoring of blood pressure and ECG was 
commenced. Subsequently, an intra-arterial catheter (20G) was inserted into 
a radial artery.
An epidural catheter was inserted at level T3-T4 using the hanging drop 
technique. A test dose of 3 mL lidocaine, 2%, was injected. After this test dose
5-1 OmL bupivacaine, 0-5%, with epinephrine, 5jig mL-1, was injected, 
depending on the height and weight of the patient and the extension of the 
blockade after the test dose.
Induction of general anaesthesia with thiopentone (5-7 mg kg-1) was 
followed by relaxation with pancuronium (0-1 mgkg“ 1). After endotracheal 
intubation, anaesthesia was maintained with a mixture of 67% nitrous oxide in 
oxygen with halothane 0-3-0-5% inspired concentration. Relaxation was 
maintained with pancuronium, 1-2 mg IV. Respiration was controlled at an 
end tidal CO2 between 4 and 4-5 vol.%. Concomitant therapy was noted on the 
medication form. Care was taken to observe the protocol of the study that no 
narcotic analgesic except nicomorphine was used.
Patient groups
The nicomorphine injections were given during maintenance of anaesthesia 
after the start of surgery when the patient’s condition was stable. The
demographic data of the patients are listed in Table 2.
Drugs
Nicomorphine (DNM), 3-mononicotinoylmorphine (3MNM), 6-mononico- 
tinoylmorphine (6MNM), morphine (M), and Vilan® were obtained from
Table 2. Demographic data of the patients
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Patient
No. Gender
Age
(years)
Height
(cm)
Body
weight
(kg)
ASA
class Surgery
1 M 70 178 88 II Thoracotomy lobectomy
2 M 63 163 53 III Thoracotomy lobectomy
3 M 66 175 80 III Thoracotomy pneumonectomy
4 M 59 183 72 I Thoracotomy lobectomy
5 F 53 169 72 II Thoracotomy lobectomy
6 M 50 175 57 II Thoracotomy lobectomy
7 F 26 180 57 I Chest wall correction
8 M 51 180 90 III Thoracotomy lobectomy
9 M 23 184 58 I Chest wall correction
10 M 16 175 50 I Chest wall correction
Mean ( ± SD) 48=1= 19 176 =b 6 68 dtz 15
Nourypharma (Oss, the Netherlands). Morphine-3-glucuronide (M3G) and 
morphine-6-glucuronide (M6G) were obtained from Sigma (St. Louis, MO,
U.S.A.).
Sampling
Blood samples of 5 mL were taken just before and at regular time intervals 
during and after anaesthesia: 1, 2, 3,4, 5, 6, 7, 8, 10, 15, 20, 30, 45, 60, 90, 120, 
and 240 min after the administration of nicomorphine in patients 1-7. In 
patients 8-10, sampling was continued for a longer period: 6, 8, 12, and 24 h 
after the administration of nicomorphine. The samples were centrifuged at 
3000 rpm and the serum was stored at — 20°C prior to analysis.
Sample preparation
i
DNM, 6-MNM, and M were extracted with the Baker-10 extraction system 
(Baker Chemicals, catalogue No. 70180, Deventer, the Netherlands) fitted with 
1 mL disposable extraction columns as a cleaning-up procedure. The extraction 
columns, packed with cyanopropylsilane bonded to silica gel (CN, Baker, 
catalogue No. 7021-01), were conditioned with two column volumes of 
methanol, two column volumes of water, and 1 mL 500 mM diammonium- 
sulphate (pH 9*3).
Serum (0*6 mL), diluted with an additional 0-5 mL of 500 mM 
diammoniumsulphate buffer (pH 9-3), was brought onto the column. The 
column was washed with 2mL of 50mM diammoniumsulphate (pH 9*3). The
«
sample was eluted with 2mL chloroform/isopropanol (90/10 v/v). The organic
i , ’
u
>' 4
*  '  .
' « \> •
. >
I *
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phase was evaporated to dryness under a mild stream of nitrogen at 37 °C, and 
the residue dissolved in 200 jiL water. Both morphine glucuronides were 
quantified simultaneously with morphine under slightly modified conditions. 
The solid phase extraction of 0-5 mL serum was carried out on 1 mL cyclohexyl 
cartridges (C6H6, Baker, catalogue No. 7212-01). It was washed with 2mL of 
50 mM diammoniumsulphate (pH 9-3) and eluted with 0-5 mL 0 01 M K H 2P0 4 
buffer, pH 2*1, containing 11% acetonitrile.
HPLC conditions
Nicomorphine and its unconjugated metabolites 3MNM, 6M NM , and M 
were determined by means of HPLC as previously described.6
Morphine and its glucuronides were separated on a Cp-Sper C8 column 
(Chrompack, Bergen op Zoom, the Netherlands). The mobile phase was a 
0*01MKH2P0 4 buffer, pH 21, containing 11% acetonitrile and O ^g L “ 1 
heptane sulphonic acid. At a flow rate of 2mLmin~1, M3G was detected 
with UV detection achieved at 210 nm (Spectroflow 773, Separations, HI- 
Ambacht, the Netherlands) at a retention time of 2-3 min. Both M 6G and M 
are electrochemically active and were quantified using an ESA electrochemical 
detector (ESA, Kratos, Rotterdam, the Netherlands) equipped with an 
analytical cell (model 5010). The detector 2 potential was set at 0-4 V, while 
detector 1 potential was 0-3 V in order to minimize interfering peaks. The 
retention times were 2*8 min and 3*5 min for M 6G and M, respectively.
Recovery and reproducibility
Calibration curve. The calibration curves, containing six data points, were 
prepared by adding a variable quantity of stock solution to blank serum or 
urine. The calibration samples for electrochemical detection and UV detection 
were prepared separately. The calibration graphs were linear for M  in con­
centrations ranging from 5 to SOOngmL“ 1 (r—0*9975), for 6M NM  in 
concentrations ranging from 2 to SOOngmL^ 1 (r = 0*9915), for 3MNM in 
concentrations ranging from 10 to 300ngmL_1 (r = 0*9810), and for 
nicomorphine in concentrations ranging from 9 to SOOngmL“ 1 (r= 0-9965). 
After extraction of patient samples, the sample had a volume of 200 jJL. 
This enabled injection of the same sample simultaneously on both HPLC 
systems: 20 \xL for electrochemical detection and 100 \iL for UV detection. The 
quantitation limit for morphine is 5ngmL_1 and that for 6M NM  is 
2ngmL~1; for 3MNM, lOngmL"“1; and 9ngmL“‘I for nicomorphine.
For the measurement of M 3G, M 6G, and M, the calibration samples 
contained all three compounds. In serum all calibration graphs, containing 
six data points, were linear: for M3G the concentrations ranged from 25 to 
580 ngm L “" 1 (r«  0*9992), for M 6G the concentrations ranged from 5 to
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lOOngmL -1  (r — 0-9982), and for M from 5 to 90ngmL~1 (r = 0’9963). The 
quantitation limit was 25ngmL~1 for M3G and 5ngmL~~l for M 6G and M, 
The recovery of the solid phase extractions was determined by comparing 
the slopes of the calibration curves (six different concentrations) of the water 
standards before and after extraction (slope before/slope after extraction x 
100%). The extraction recoveries of the serum standards and water standards 
were identical. The recoveries from the cyanopropyl extraction procedure for 
nicomorphine, 6~ and 3-MNM, and M were 69%, 96%, 91%, and 87%, 
respectively. The percentages of recovery from the cyclohexyl extraction 
procedure for M3G, M 6G, and M were 96, 97, and 97, respectively.
Procedure for the detection of glucuronides
Deglucuronidation was carried out with p~glucuronidase type H -2  from 
Helix pomatia (G-0876, Sigma, St. Louis, U.S.A.). A sample of 100 [iL was 
mixed with 25\xL fi-glucuronidase type H ~2 and 125 \xL buffer (0*2 M sodium 
acetate, pH 5*0). The reaction was carried out overnight and was stopped by 
addition of 800p.L500mM diammoniumsulphate buffer, pH 9-3, followed 
immediately by the extraction procedure. Both morphine glucuronides are 
commercially available in pure crystalline form, and calibration samples, with 
known amount of glucuronides, were subjected to this reaction. Under these 
conditions the glucuronides completely disappeared from the chromatogram, 
while there was an equal increase in morphine concentration, taking the 
differences in molecular weight into account. When the amount of glucuronide 
was too small to be weighed accurately, the deglucuronidation was used to 
quantify the standard solution. Also patient samples were subjected to this 
deglucuronidation procedure to determine the presence of morphine-3 , 6- 
diglucuronide or unknown sulphate conjugates. These sulphate conjugates 
could be released by the enzyme aryl sulphatase also present in the enzyme 
preparation of Helix pomatia. When patient samples were subjected to this 
deglucuronidation, no additional morphine was found, as was expected from 
the former concentrations of M3G, M 6G, and M.
Pharmacokinetics
All pharmacokinetic calculations10 were carried out using the computer 
package MW /PHARM obtained from Mediware (Groningen, the 
Netherlands). Peak serum concentrations Cmax (ngm L"1), occurring at /max 
(h), were read from the fitted serum concentration-time curve. The t\j2 values 
were calculated from the slope of the terminal portion of the semilogarithmic 
serum concentration-time curve by linear regression analysis. The area under 
the serum concentration-time curve (AU Cq^) was calculated from the data of 
the fitted curve and extrapolated to infinite time. Total body clearance (CL) 
was calculated as dose/AUCo ^  (assuming F= 1).
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Statistics
p values were calculated using analysis of variance according to standard 
procedures. Statistical difference was defined at p<  0-05.
RESULTS
In all studied patients the parent compound and the metabolites 6- 
mononicotinoylmorphine, morphine, morphine-3-glucuronide, and 
morphine-6-glucuronide could be detected in serum. Figures 1 and 2 show 
exemplary serum concentration-time curves of nicomorphine and its 
metabolites in two patients (No. 8 and 10, respectively). Figure 1(a) (patient 
8) shows that nicomorphine was absorbed rapidly from the epidural space. The 
concentration was highest in the first serum sample and gradually decreased 
thereafter, and thus resembled an intravenous injection (pseudointravenous 
injection). The apparent half-life is 0*135h ( = 8 min). The metabolite 6- 
mononicotinoylmorphine appeared instantaneously in the serum and shows a 
biphasic serum elimination curve with an apparent terminal elimination half- 
life of l*9h. Morphine was present in the first serum sample, reached a 
maximum at 5min, and was eliminated with an apparent half-life of l-9h. 
Figure 1(Z>) (also patient 8) shows the serum concentration-time curves of 
morphine and its two metabolites on a larger time scale. The morphine 
conjugates were detectable after lOmin. The apparent half-lives are 4*0 and 
2*9 h for M3G and M 6G respectively.
Figure 2(a) (patient 10) shows that nicomorphine was absorbed from the 
epidural space and reached a maximum at 0*120 h. The apparent half-life of 
nicomorphine was 8 min. The metabolite 6-mononicotinoylmorphine shows a 
biphasic plasma elimination curve with an apparent terminal elimination half- 
life of 2*1 h. Figure 2(A) (patient 10 on a larger time scale) shows that morphine 
and the glucuronides (M3G and M 6G) are running parallel with apparent 
elimination half-lives of 3*8 h, 3*5 h, and 3*6 h respectively.
Table 3 summarizes the kinetic parameters of nicomorphine, 6-MNM, M, 
M3G, and M 6G for the time interval 0-4 h after administration of 
nicomorphine in all 10 patients. Table 4 summarizes the pharmacokinetic 
parameters of all compounds in patients 8-10, who were sampled for a longer 
period of time; 24 h.
DISCUSSION
This study shows that after epidural administration, the parent compound 
exists in the serum of the human body only for 30 min. The rapid elimination
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(a) 1 -q serum conc ug/ml
Nicomorphine
15 mg epiduraliy
0.1 — ........ .......... M3G t1/2 4.0 h
...............
-O
6MNM t)/2 1.9 h
M6G t,/a 2.9 h
DNM t1/2 0.1 M t)/2 1.9 h
0 .001-
0
0
I
1
T
2
T
3
T
4
T
5
1
6 h
(b) 1 -3  serum conc ug/ml
0.1
0.01 “r
0.001 —  
0
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»»»IN
Nicomorphine
15 mg epiduraliy
t,/a 4.0 h
M6G t,„ 2.9 h1/
M 1,9 h
T
5
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T
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T
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n _
30 h
Figure I. The serum concentration time curvcs of nicomorphine (DNM) and its metabolites 
6 -mononicotmoylmorphine (6MNM), morphine (M), morphine-3-glucuronicie (M3G), and 
morphine*6-glucurornde (M 6G) in patient 8 after an epidural dose of 15 mg nicomorphine
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Figure 2. The serum concentration-time curves of nicomorphine (DNM) and its metabolites 
6MNM, M, M3G, and M6G in patient 10 after an epidural dose of 15 mg nicomorphine
Table 3* Pharmacokinetic parameters of nicomorphine and its metabolites after an epidural dose of 15 mg (time interval 0-4h); tiji&zy 
half-life of elimination of the different phases; maximum serum concentration; time at which Cmax occurs; A U C ^  (jighL- 
area under the serum concentration-time curve extrapolated to t = co; CL, total bodyl clearance; ratio AUC=AUQM(M3G)/
A U C^M ) and AU Qm(M6G)/AU C^Qvi) respectively
Parameter
Nicomorphine
Cmax (ngmL-1)
‘mix (h)
AUCo.x (ughL-1)
CL (Lh">)
‘\a (h)
MRT (h)
6-mononicotinodylmorphine 
Cjjjax mL
tjnax (^)
AUCn_^ OighL-1)0-x?
I1/2(2)
Morphine
C™, (ngmL-1)
tmax 00
AÜC.M (ngmL-1) 
Morphine-3-glucuronide 
Cm*x (ngmL“1)
AU C^(!ighL-‘) 
ratio AUC (M3G/M)
Morphine-6-glucuronide 
Cm** (ngmL"!)
(^)
AU C^ ûighL“1)
ratio AUC (M6G/M)
Patient
1 2 3 4 5 6 7 8 9 10 Mean ± SD
102 79 98 106 72 137 40 301a 43 46 80 ±33
0*072 0*028 0*056 0*132 0*084 0*258 0*149 0-01T 0*070 0*120 0*108 ±0*068
23 18 27 38 22 86 16 34 20 14 24 ± 8
655 842 551 393 673 174 919 441 756 1074 648 ±268
0*107 0*147 0*158 0*164 0*181 0*161 0*166 0*135 0*303 0*130 0*165 ±0*053
0-20 0*23 0*26 0-32 0*32 0-49 0*33 0*14 0-49 0-27 0*31 ±0*11
15 9 28 30 33 38 22 47 22 23 27 ±11
0*12 0*11 0*08 0*19 0*15 0*49 0*15 0*07 0-17 0*14 0*17±0*12
28 8 73 76 37 55 27 86 11 25 43 ±28
0*45 0*09 0*12 0*17 0*18 0*002 0*07 0*12 - 0*07 0*14 rb 0*13
1*67 1*04 3*64 3-99 1*32 0-44 1*35 1*92 0-23 2*09 1*77 ±1*23
2*18 1*37 5*01 5-14 1*60 1*04 1-80 2*64 0*44 2*52 2*37 ±1*57
9 20 16 12 14 20 b 20 11 18 16±5
0*57 0*72 0*67 0*39 0*52 0*68 b 0*08c 0-38 0-34 0*53±0*15
32 50 43 24 33 42 b 22 37 48 37± 10
80 125 146 102 87 161 b 138 100 164 123 ±32
2*40 1*83 2*23 1*29 1*65 1*51 b 0*43 1*60 1*73 1*63 ±0*57
324 495 698 358 340 577 b 420 381 625 469 ±137
10*1 9*9 16*2 14*9 10*3 13*7 b 19-1 10*3 13*0 13*1 ±3*2
12 18 24 15 15 21 14 16 13 23 17 ± 5
2*74 1*73 2*09 1*46 1*76 1-40 1*63 0-73 1*50 1*96 1*70 ±0*52
53 68 102 53 57 73 50 45 45 83 63 ±19
1*7 1-4 2*4 2*2 1*7 1*7 2*0 1*2 1*7 1*78 ±0-37
I—k
o.
TJ
2
»
7*
O
0
s
>
z1
*
§
>
ha
f-1
a*Pseudo intravenous’ injection: the value of the first sample is C, 
cNot included.
max (at values are not included in mean ± SP* bAt the top of the curve at about 4 h
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Table 4. Pharmacokinetic parameters of nicomorphine and its metabolites after an 
epidural dose of 15 mg (a final sampling time of 24 h): half-life of elimination of
the different phases; C„mx) maximum serum concentration; fmax, time at which Cmax 
occurs; AUC()._:/J (ug h L-'), area under the serum concentration-time curve 
extrapolated to t = oo; CL, total body clearance; ratio AUC0_4 and ratio AUCq.«, 
(M3G/M), difference not significant, /? = 0-59; ratio AUQm and ratio AUCV«,
(M6G/M), difference not significant, p — 0-38
Patient
Parameter 8 9 10 M eaniSD
Nicomorphine
Cmax (ngmL“1)
'max (fy)
AUCq-od ftighL”1)
CL (Lh~0
t w2 (h)
MRT (h)
6-mononicotinoylmorphine
'mux (^)
AUC0..oo OighL“1)
'1 /2(a) (h)
Morphine
*^mnx (^g UlL )
'max (W
AUCm  C^ghL-1)
AUG*.* OighL"1)
him  (h)
( i ¿2JWLW
M RT (h)
Morphine 3-glucuronide 
m^ax (ngmL )
'max (W
AUCo.4 (^ighL-1)
ratio AUC0 4 
AUC0 (X5 (lighL^1) 
ratio AU Co .oo
t\n (h)
MRT (h)
Morphine 6-glucuronide
cmm (ngmL-1)
( )
AUCo.4 (UghL-1)
ratio AUC0 4 
AUC0.œ (ughL-1) 
ratio AUC0 to
hii (h)
MRT (h)
301a 43
0'017a 0*070
34 20
441 756
0*135 10*303
0*14 0-49
47 22
0-07 0*17
86 11
0*12 ------------
1*92 0*23
2*64 0*44
20 11
0-08b 0*38
22 37
27 81
0*19 - ----------
1-93 5*17
2*43 7*59
138 100
0-43 1*60
420 381
19*1 10*3
862 853
31*9 10*5
4-07 4*68
6*03 7*36
16 13
0*73 1*50
45 45
2*0 1*2
79 130
2*9 1*6
2*94 6-05
4*55 9*38
46 45 ± 2
0*120 0*10 ± 0*04
14 23 ± 10
1074 757 317
0*130 0*189 ±0*098
0*27 0*30 ±0-18
23 31 ±14
0*14 0*13±0*05
25 41 ±40
0*07 0*10 ±0*04
2*09 1*41 ±1*03
2*52 1*87 ± 1*24
18 16 ± 5
0*34 0*36 ±0*03
48 36 ±13
90 66 ± 34
0-11 0*15±0*06
3*78 3*63 ± 1 -63
5*46 5*16 ±2*59
164 134 dr 32
1*73 1*25 ±0*72
625 475± 131
13*0 14*1 ±4*5
1161 959 ±175
12*9 18-4± 11*7
3*54 4*10 ±0-57
5*91 6*43 ±0*80
23 17±5
1*96 1-40 ±0*62
83 58 ±22
1*7 1*6 ±0*4
162 124 ±42
1*8 2*1 ±0*7
3*60 4*20 ±1*64
6*20 6*71 ±2*46
“ Pseudointravenous injection: the value of the first sample is CroM (at imM); values are not included
in mean±SD.
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from the serum may be due to a large distribution over the tissues due to the 
high lipid solubility of nicomorphine and to a high rate of metabolism. 
Nicomorphine (Vilan®) in the injection fluid is stable (product information).
The metabolite 6-mononicotinoylmorphine is present instantaneously in the 
serum while 3-mononicotinoylmorphine could not be detected. The compound 
3-mononicotinoylmorphine is unstable in solution (stock solution, blood) with 
rapid hydrolysis into morphine.
In 6-mononicotinoylmorphine glucuronidation is only possible at the 3 
position, yielding 6MNM3G. However, no peak in the chromatogram is 
present at a retention time that would fit such a compound. Moreover, 
treatment of the serum samples with p-glucuronidase did not result in the 
increase of the concentration of 6-mononicotinoylmorphine, while under these 
conditions M3G and M 6G were converted completely to morphine.
Morphine was present in all patients within 5 min after dosing, and reached 
a maximum after 0*53 h (mean). The apparent elimination half-life of morphine 
can only be calculated from the data from patients 8-10, and varied from 1 -9 h 
to 5 ‘2 h (mean 3-63h± 1*63h) as was reported in the literature. u ~13
Morphine is glucuronidated at the 3 and 6 positions. These two glucuronide 
conjugates were present in plasma. 14“16 Morphine-3-glucuronide has been 
shown to be a potent functional antagonist of morphine and morphine-6- 
glucuronide antinociception after intracerebroventricular administration to 
rats.17*18 The conjugate morphine-6-glucuronide contributes to the analgesic 
effect. 19*20 In patients 1 -8  it is only possible to calculate AUC0.^  because the 
elimination phase is about to begin. In patients 8-10 the AUCq ^  can be 
calculated as well as the A U Q ,4 . Comparison of the ratios of AUC M3G/M 
and M 6G/M do not show a significant difference between the ratios of 
AUQ)~oo and AUQm- The mean apparent terminal half-lives of the two 
morphine glucuronides are 4*10h (±0*57h) for M3G and 4-20h (i: l*64h) for 
M 6G, and do not differ significantly from each other or from the half-life 
of morphine, 3-63hd=l’63h (p>0-8). Hanna et a/ .21 found that after 
administration of morphine, M 6G declined in parallel with morphine in the 
terminal phase. As no attention was given to M3G, no conclusions can be 
made about the competing pathways. It would have been of importance to 
measure M3G, since it is present in larger concentrations, due to enterohepatic 
circulation and deglucuronidation in the intestine, and thus could be a source 
of morphine in the terminal phase.
In patient 8 (Figure I) the elimination half-lives of morphine and the two 
glucuronides are not the same: l*9h (M), 4*0 h (M3G), and 2*9 h (M 6G). As 
morphine reaches its maximum serum concentration as soon as 0*08 h after 
dosing, it resembles an intravenous injection. In our earlier studies concerning 
intravenous injections of 10, 20, and 30 mg nicomorphine, morphine reached 
its maximum concentration in less than 0-1211 and we found similar results: the 
apparent half-life of morphine (mean 2-0 h) was smaller than the apparent half- 
lives of both glucuronides (mean 3*8 h).
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In patient 10 (Figure 2) it takes 0-34 h to reach the maximum serum 
concentration (18 ngmL“1), which is comparable to the maximum reached in 
patient 8, 20 ngmL-1)- The apparent elimination half-life of morphine is 
similar to that of M3G and M6G. In this case, deglucuronidation of the 
morphine glucuronides in the intestine, and the enterohepatic recirculation, 
govern the terminal half-life of morphine.22-23 In the final elimination phase 
glucuronidation/deglucuronidation reaches an equilibrium, with the renal 
excretion and faecal excretion as the terminal elimination pathways.24-26
In patient samples, the increases in morphine concentration after 
deglucuronidation was completely accounted for by the initial presence of 
M3G and M6G. This means that no diglucuronide was present.27
In conclusion, after epidural administration the prodrug 3, 6- 
dinicotinoylmorphine is biotransformed into three (active) metabolites: 6- 
mononicotinoylmorphine, morphine, and morphine-6-glucuronide.
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